Welcome
Support Centre
02 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ ...Back to search results ] [ Print-friendly version ]
The effects of Nocturnal Haemodialysis (NHD) compared to conventional haemodialysis on progression of Left Ventricular (LV) mass: a randomised controlled pilot study
ISRCTN ISRCTN25858715
DOI 10.1186/ISRCTN25858715
ClinicalTrials.gov identifier
EudraCT number
Public title The effects of Nocturnal Haemodialysis (NHD) compared to conventional haemodialysis on progression of Left Ventricular (LV) mass: a randomised controlled pilot study
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Nocturnal haemodialysis and conventional three times per week haemodialysis will not differ with respect to progression of LV mass (measured using Cardiac Magnetic Resonance [CMR]) at 6 months.
Lay summary
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain End-stage kidney disease
Participants - inclusion criteria All adult haemodialysis patients in Alberta, Canada are eligible.
Participants - exclusion criteria Patients who are unable to perform NHD due to physical or mental incapacity.
Anticipated start date 01/08/2004
Anticipated end date 30/06/2006
Status of trial Completed
Patient information material
Target number of participants 38 subjects
Interventions Subjects are randomised to nocturnal haemodialysis or conventional three times per week haemodialysis (controls).
Primary outcome measure(s) Change in left ventricular mass (measured by CMR) at 6 months.
Secondary outcome measure(s) 1. Mean change in systolic Blood Pressure (BP)
2. Change in HRQOL (Health-Related Quality-Of-Life)
3. Mean change in Haematocrit (Hct)/Erythropoietin (Epo) ratio
4. Mean change in calcium - phosphorus product
Sources of funding Kidney Foundation of Canada (Canada)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17878421
Contact name Dr  Bruce  Culleton
  Address Foothills Hospital
1403-29th ST NW
  City/town Calgary
  Zip/Postcode T2N 2T9
  Country Canada
  Tel +1 403 944 8166
  Fax +1 403 270 0055
  Email bruce.culleton@calgaryhealthregion.ca
Sponsor Kidney Foundation of Canada (Canada)
  Address 300-5165 Sherbrooke ST W
  City/town Montreal, Quebec
  Zip/Postcode H4A 1T6
  Country Canada
  Email research@kidney.ca
  Sponsor website: http://www.kidney.ca/
Date applied 08/09/2004
Last edited 20/09/2007
Date ISRCTN assigned 19/10/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.